July 25, 2016
(The Guardian) – In September 2015, Parrish, then 44, flew to Colombia to receive two experimental gene therapies. One was a myostatin inhibitor, a drug that is being tested as a treatment for muscle loss. The other was a telomerase gene therapy – the drug that BioViva claims has reversed her cells’ biological age, by lengthening parts of her genetic material called telomeres.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.